Jagsonpal Pharmaceuticals Ltd. · NSE:JAGSNPHARM
Jagsonpal Pharmaceuticals — Q3 FY2025 Earnings Presentation
24 slides from Jagsonpal Pharmaceuticals's earnings presentation, Jan 23, 2025
Slide 1: Press Release for Quarter and Nine Months Ended December 31, 2024
A CSR Initiative JAGSONPAL PHARMACEUTICALS LIMITED Corporate Office: Nimai Tower, 3rd Floor, Plot No. 412-415, Phase-IV, Udyog Vihar, Gurugram -122015, Haryana (India) January 22, 2025 The Department of Corporate Services- Listing The Department of Corporate Services- Listing BSE Ltd, National Stock
Slide 2: Jagsonpal Pharmaceuticals announces Q3FY25 and 9MFY25 Results
Jagsonpal Pharmaceuticals announces Q3FY25 and 9MFY25 Results Q3FY25 Revenue at ₹740 Mn, 57% growth over Q3FY24 Q3FY25 Operating EBITDA at ₹171 Mn, margin at 23% Gurugram, January 22, 2025: Jagsonpal Pharmaceuticals Limited (BSE: 507789, NSE: JAGSNPHARM) today announced the unaudited financial resul
Slide 3: Management commentary and about the company
Commenting on the performance for the quarter, Manish Gupta, Managing Director and CEO, Jagsonpal Pharmaceuticals Limited said, “I am pleased with the Q3FY25 performance that is reflective of the strategic choices we have made. With revenues of ₹740 million, a 57% growth YoY, and a 183% YoY increase
Slide 4: Jagsonpal Pharmaceuticals Limited Q3FY25 & 9MFY25
Jagsonpal Pharmaceuticals Q3FY25 & 9MFY25 Limited Investor Presentation January 2025
Slide 5: Safe Harbor
Safe Harbor This presentation contains statements that constitute “forward looking statements” including and without limitation, statements relating to the implementation of strategic initiatives, and other statements relating to our future business developments and economic performance. While these
Slide 6: About the Company
About the Company 3
Slide 7: Science-driven Pharma Company
Science-driven Pharma Company ❑ Established in 1978, boasting a legacy of 46 years. ❑ Among the top 10 companies in the gynaecology segment. ❑ Strong sub-chronic portfolio, less prone to genericization. ❑ Long-standing heritage and brand equity with medical professionals. Key Therapeutic Segments GY
Slide 8: Building A High-impact Asset Light Model
Building A High-impact Asset Light Model Capital Intensive Activities - Out-Sourced Ideation PAN-India Distribution o In-house Ideation For Research & Contract o 900+ Medical Reps for Innovative Drug Concepts. Development Manufacturing brand promotion 1-2 New Product Launches o 18 stocking points ac
Slide 9: Strong Presence in Key Therapies
Strong Presence in Key Therapies Gynaecology Orthopedics ▪ 10th as per CMARC RPM in CVM ▪ 2nd as per CMARC RPM in CVM ▪ Regular connect with 25,000 of 32,000 01 02 ▪ Regular connect with 75% practicing Gynecologist Orthopedics ▪ Leaders in Progesterone therapeutic Gynaecology Orthopedics ▪ Strong pr
Slide 10: Strategic Pillars
Strategic Pillars Innovation - Large, well Niche Molecules, trained Work Dominant Market Force of 900+ Share Medical Reps Lean Operations: Inorganic Growth Asset Light Powered by Model Strategic Acquisition 7
Slide 11: Network of Experienced Medical Reps
Network of Experienced Medical Reps Well trained and experienced 900+ medical representatives across all their therapeutic areas Pharmacies to ensure efficient 1.25+ Lk product delivery States across the nation served 28 through extensive distribution network Prescribers trust, endorsed Mother Wareh
Slide 12: Strategic Leap with Yash Pharma
Strategic Leap with Yash Pharma JAGSONPAL PHARMACEUTICAL LTD YASH PHARMA LABORATORIES PVT LTD Expertise Innovation Scale Expertise Innovation Scale o 4 Decade of o Key Therapeutic o Strong Northern & o 5 Decade of o New segments: o Strong Eastern and Experience areas: Gynecology & Eastern presence E
Slide 13: Robust Financial Momentum
Robust Financial Momentum Revenue (Rs Mn) Operating EBITDA (Rs Mn)* 2,367 2,176 2,087 2,102 482 1,879 434 1,586 364 250 191 85 FY20 FY21 FY22 FY23 FY24 9MFY25 FY20 FY21 FY22 FY23 FY24 9MFY25 PAT (Rs Mn) Resilient Margins 316 23% 267 18% 17% 225 171 189 16% EBITDA 10% 12% margin 11% 11% 9% 9% PAT mar
Slide 14: Driving Growth with Efficiency and Strong Returns
Driving Growth with Efficiency and Strong Returns Enabling Shareholders’ Return Net Debt (Rs. Mn) 64% FY20 FY21 FY22 FY23 FY24 9MFY25 60% 57% -340 -252 37% 34% ROE -534 ROCE 14% 17% 18% 10% 14% 12% -1,146 7% -1,321 FY20 FY21 FY22 FY23 FY24 9MFY25* -1,479 Free Cash Flow (Rs. Mn) 463 440 349 o Maximiz
Slide 15: Real World Impact: Beyond The Bottom Line
Real World Impact: Beyond The Bottom Line Shaping the Future Driving Menopause Empowering Women Transforming Awareness Through MySakhi Hygiene Access Expanding outreach with Deliver impactful virtual A dedicated website Built modern sanitation self-testing kits, sessions on menopause, offering educa
Slide 16: Q3FY25 & 9MFY25 Performance
Q3FY25 & 9MFY25 Performance 13
Slide 17: Management Commentary
Management Commentary I am pleased with the Q3FY25 performance that is reflective of the strategic choices we have made. With revenues of ₹740 million, a 57% growth YoY, and a 183% YoY increase in operating EBITDA (pre-ESOP) to ₹171 million, our performance demonstrates an effective alignment of our
Slide 18: Operational Highlights: Q3FY25
Operational Highlights: Q3FY25 Sales Momentum Accelerates Achieved ₹ 740 Mn in quarterly sales, marking a robust 57% growth compared to Q3FY24. Acquisition Integration Success Successfully integrated the acquired business, with Q3FY25 as the second full quarter delivering performance in line with ex
Slide 19: Key Brand Progression (Source: IQVIA)
Key Brand Progression (Source: IQVIA) (All values in Rs. Mn) 9MFY25 Qtr FY24 Qtr Brand Growth% MAT Dec’24 MAT Dec’23 Growth% Avg. Avg. Jagsonpal 1,060 734 44% 4,120 3,063 35% Indocap 140 104 35% 520 430 21% Maintane Injection 100 88 14% 380 370 3% Metadec 80 79 1% 320 330 -3% Divatrone 50 72 -31% 23
Slide 20: Financial Highlights: Q3 & 9MFY25
Financial Highlights: Q3 & 9MFY25 (All values in Rs. Mn) Revenue from Operations Gross Profit & Margin (%) EBITDA & Margin* (%) PAT* 740 475 171 115 472 277 60 40 58.6% 64.2% 12.8% 23.1% Q3FY24 Q3FY25 Q3FY24 Q3FY25 Q3FY24 Q3FY25 Q3FY24 Q3FY25 2,102 1,354 482 316 1,029 1,652 314 189 62.3% 64.4% 19.0%
Slide 21: Financial Results: Q3 & 9MFY25
Financial Results: Q3 & 9MFY25 (All values in Rs. Mn) Particulars Q3FY25 Q3FY24 Q2FY25 9MFY25 9MFY24 Revenue from Operations 740 472 747 2,102 1,652 Total Expenses 569 412 563 1,620 1,338 EBITDA 171 60 184 482 314 EBITDA Margin 23.1% 12.8% 24.6% 22.9% 19.0% Other Income 23 25 17 54 68 ESOP Cost 13 2
Slide 22: Key Balance Sheet Items
Key Balance Sheet Items (All values in Rs. Mn) Particulars 31-Dec-24 30-Sep-24 Movement Shareholders Funds 2,319 1,971 348 Tangible Assets 8 10 -2 Intangibles 875 894 -19 Right of Use Assets 86 90 -4 Assets Held for Sale 0 172 -172 Financial Assets (Cash & Equivalents) 1,321 934 387 Other Non-Curren
Slide 23: Growth Outlook
Growth Outlook The 3-Pronged Growth Strategy Outlook – FY25 and Beyond New Product Launch ▪ Innovation-Driven Growth FY25 ▪ Launch 4-6 products annually, driving market engagement and revenue. 30%+ ~22% Revenue Growth Operating margins Volume Growth (pre-ESOP) ▪ Sales Force Empowerment ▪ Targeted tr
Slide 24: Thank You
Thank You Feel free to reach out to us if you have any questions. JAGSONPAL PHARMACEUTICALS LTD. INVESTOR RELATIONS Corporate Office: Nimai Tower, 3rd Floor, Devyanshi Dave Plot No. 412-415, Phase-IV, Udyog Vihar, Email: Devyanshi@goindiaadvisors.com Gurugram -122015, Haryana (India) Ph: +91 9892330
Jagsonpal Pharmaceuticals — Q3 FY2025 Earnings Presentation on 6ix